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Influenza viruses infect millions of people each year, leading to several hundred thousand 
hospitalizations and thousands of deaths annually in the US. Early antiviral therapy reduces 
illness duration, complications, and mortality associated with influenza. Yet, antivirals are 
consistently used at a suboptimal rate. Patients with positive influenza diagnostic testing 
results are more likely to receive antiviral therapy and less likely to be prescribed 
unnecessary antibiotics. Thus, access to reliable influenza testing in both ambulatory and 
inpatient settings is critical to facilitate both optimal patient outcomes and antimicrobial 
stewardship. Recently, the first point-of-care (POC)7 molecular diagnostic test was cleared 
by the US Food and Drug Administration (FDA) for the detection of influenza. At the same 
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time, concerns about the performance of commonly used rapid antigen tests, particularly the 
test sensitivity, led to modified regulatory requirements for these devices. The landscape of 
influenza diagnostics is rapidly evolving, and clinical laboratorians are certain to face 
pressure regarding new testing modalities. In this article, 5 experts that span the continuum 
of influenza diagnosis from the clinical laboratory to industry to public health and regulatory 
agencies discuss recent advances and ongoing challenges in influenza diagnostics.
During influenza season, how does rapid influenza diagnostic testing affect 
clinical management and clinical workflows?
Neil Anderson: During influenza season, most infected individuals will present to 1 of 2 
places: an outpatient clinic or an emergency department (ED). These initial interactions with 
the healthcare system are often very brief. During this short amount of time, clinicians must 
make many decisions. Should the patient be given antibiotics, antivirals, or neither? Should 
the patient be admitted? Given the overlap in symptomatology of different respiratory 
pathogens, these questions can be very difficult to answer on presentation alone. In this 
situation, a rapid influenza diagnostic test is an essential component of patient management 
during influenza season. In both outpatient and ED settings, the identification of patients 
who tested positive for influenza enhances the likelihood that antiviral treatment is promptly 
initiated, if appropriate. Additionally, real-time influenza diagnosis promotes antimicrobial 
stewardship by avoiding unnecessary antibacterial therapy. Finally, if the patient is admitted, 
a rapid diagnosis of influenza can help inform early appropriate infection prevention 
measures to prevent nosocomial influenza virus transmission to vulnerable inpatients.
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Ritu Banerjee: Rapid influenza diagnostics can provide rapid, actionable results that aid 
clinical decision-making for patients with respiratory symptoms who present during cold 
and flu season. In the outpatient setting, when patients have positive influenzatest results but 
relatively mild infections that do not require hospitalization, providers aremore likely to 
prescribe antivirals like oseltamivir and less likely to prescribe unnecessary antibiotics or 
perform ancillary testing like blood tests and chest radiographs. A high-risk 
immunocompromised patient with a positive influenza test result may be followed more 
closely oreven hospitalized. Providers are more likely to prescribe antiviral prophylaxis for 
high-risk contacts of the known positive patients and reinforce the importance of staying 
home from school or work to limit influenza virus spread in the community. Rapid influenza 
testing also has direct implications for patient flow, as rapid results enable faster discharge 
from EDs or outpatient clinics, which is especially important during winter months when 
respiratory viruses are prevalent and clinics are busy.
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Christine Ginocchio: During traditional “flu seasons,” influenza is responsible for 
anywhere from <5% to approximately 35% of respiratory tract infections. Depending upon 
the epidemiology of a given flu season, many respiratory tract infections denoted as 
influenza-like illness are due to other circulating respiratory viruses that cannot be reliably 
distinguished from influenza on clinical symptoms alone. Therefore, rapid influenza tests 
can assist with clinical care and treatment decisions for patients in a variety of settings, 
including outpatient clinics, chronic care facilities, EDs, and hospitals. Rapid results (15 min 
to a few hours) allow for appropriate treatment within a time frame that is clinically relevant, 
as the most benefit from treatment of influenza is obtained if initiated within 48 h of 
symptom onset. Rapid results for influenza alone or as part of larger multiplex syndromic 
panels affect clinical decisions to admit or discharge, shorten time in the ED, reduce the 
number of other ancillary tests, shorten length of stay, and promote more effective infection 
control practices. Finally, rapid identification of an outbreak in a community or chronic care 
facility allows for appropriate public health measures.
What are some important considerations for clinical laboratories regarding 
the use of rapid influenza antigen assays? What are the strengths, 
limitations, and logistical challenges of these assays?
Neil Anderson: The greatest appeal of rapid influenza diagnostic (antigen) tests (RIDTs) is 
their ease of use. Because many of these tests are CLIA-waived, they can be performed by 
virtually any member of the healthcare team with appropriate training. Thus, rapid antigen 
testing has become commonplace in a variety of patient settings during influenza season. 
Unfortunately, challenges with test sensitivity have been well documented. The performance 
of RIDTs can be affected by the amount of virus present and the antigenic makeup of the 
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circulating strains. Sensitivity varies and is estimated to be lower than 50% for some RIDTs. 
It is important to note that many RIDTs have acceptable levels of specificity. A positive 
result during influenza season in a symptomatic patient is highly suggestive of influenza. 
This leads many to the conclusion that rapid influenza antigen testing is an acceptable 
standalone approach. However, many clinicians are unaware of the low sensitivity of these 
assays. Laboratories may issue results with comments regarding test limitations, but this is 
likely to have little effect, as most testing is performed at the POC. The reality is that antigen 
testing is frequently deployed in many settings where providers do not fully understand test 
limitations.
Christine Ginocchio: The benefits of RIDTs are fast time to results (generally 15 min), ease 
of use requiring minimal training, availability of CLIA-waived tests for office and bedside 
use, and relatively low cost. However, there are several important factors that should be 
considered if opting to use an RIDT, including for whom and when testing should be 
performed. Sensitivity can be suboptimal (ranging from 50% to 70%) depending on the 
patient population tested (generally perform better in children than in the elderly), time of 
sample collection after onset of symptoms (best within 3–4 days), quality of sample 
(preferably nasopharyngeal swab, aspirate, or wash), and the influenza virus strain 
(generally lower for influenza B viruses). Importantly, RIDTs may not detect emerging 
strains or novel variants. Specificities of RIDTs are approximately 90%–95%; hence, false-
negative results occur more commonly than false-positive results during times of high 
influenza activity. Conversely, false positives are more likely when influenza viruses are not 
circulating, and RIDTs are therefore are not recommended for use outside influenza season 
when pretest probability is low. A negative RIDT is insufficient to exclude influenza 
infection in persons with a high clinical suspicion. Healthcare personnel must be educated 
on the “real-life” performance of RIDTs, including positive and negative predictive values 
during periods of high and low influenza activity. The laboratory should also be prepared to 
offer molecular testing, either frontline or as a reflex test, when an RIDT is negative but the 
confirmation of influenza is indicated (high-risk persons, hospitalized patients, institutional 
outbreaks, risk for novel influenza A virus), to confirm a positive RIDT in low-prevalence 
times, or if subtyping is indicated.
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Kimberly Hanson: Of highest concern regarding the use of rapid antigen tests for influenza 
is the lack of sensitivity. Test performance varies by assay, specimen type, adequacy of 
collection, host, and influenza type (i.e., sensitivity is generally lower for influenza B). 
Notably, influenza A subtype information is not provided by RIDTs, and these tests do not 
differentiate seasonal strains from potentially novel strains. Thus, when a patient has 
compatible symptoms and influenza is known to be circulating in the community, a negative 
rapid test does not rule out infection, and additional testing may still be required. The main 
advantages of RIDTs include the rapid turnaround time and the ability to perform testing at 
the POC. However, use of RIDTs at the POC also presents several logistical challenges 
regarding training nonlaboratory clinical staff to appropriately collect, perform, and interpret 
testing.
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Timothy Uyeki: Clinical laboratory staff should be knowledgeable about proper specimen 
collection, transport, and processing, as well as what information is provided by RIDTs. 
RIDTs can differentiate between influenza A and B virus antigens in respiratory specimens 
but cannot differentiate among influenza A virus subtypes or distinguish seasonal influenza 
A viruses from novel influenza A viruses of animal origin. If subtyping information is 
needed or if novel influenza A virus infection is suspected in a patient, specimens should be 
sent to a public health laboratory for specialized molecular testing. Clinical laboratory staff 
should be familiar with the level of influenza activity in the community. Information sources 
can include local influenza surveillance data, positive results of influenza tests in outpatients 
and hospitalized patients, and reports of influenza outbreaks, including in long-term care 
facilities. Staff should also understand that during periods of influenza activity in a 
community, a negative RIDT result does not exclude influenza virus infection. For 
hospitalized patients with suspected influenza, the CDC does not recommend use of RIDTs, 
so clinicians should be advised not to order these tests for patients who are being admitted to 
the hospital or who are already hospitalized with suspected influenza and to order a 
molecular assay for influenza instead.
The FDA recently reclassified rapid influenza testing devices from Class I to 
Class II devices. What prompted this change? What is the significance of 
this change for clinical laboratories and will it affect patient management?
Ritu Banerjee: The lack of sensitivity of RIDTs during the 2009 H1N1 pandemic led to 
recognition by the FDA that RIDTs were contributing to missed diagnoses, treatment delays, 
and poor outcomes for patients. Reclassification of RIDTs by the FDA from Class I to Class 
II devices will improve overall test quality, as these devices must now pass minimum 
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performance requirements and meet compliance with additional controls to ensure accuracy 
and reliability. The effects of this change are not yet clear, but it may confer clinical benefit 
by improving detection of influenza-infected patients, which will facilitate directed therapy 
and reduce unnecessary use of antibiotics for uncomplicated influenza and enable 
appropriate infection control measures in the inpatient setting to prevent further spread of 
disease.
Christine Ginocchio: During the 2009 H1N1 pandemic, numerous studies demonstrated 
suboptimal sensitivity of many RIDTs. Sensitivity for the 2009 pandemic virus strain varied 
significantly from 20% to 85% depending on the assay. This gap highlighted a need for 
better regulatory oversight of RIDTs. Until 2017, RIDTs were classified by the FDA as 
Class I (low likelihood of harm and general controls are required), and there was no 
regulatory requirement for manufacturers to continually verify the performance of FDA-
cleared RIDTs. However as circulating influenza virus strains routinely undergo genetic drift 
or shift (as seen in 2009), the ability of RIDTs to detect new strains may vary considerably. 
Therefore, the FDA reclassified antigen-based RIDT systems as Class II devices to help 
improve the overall quality of influenza testing and remove poorly performing devices from 
the market. Manufacturers are now required to continually monitor antigen-based RIDT 
performance, including accuracy, reliability, and clinical relevance. Testing must be done by 
the manufacturer on an annual basis and in certain emergency situations, such as emergence 
of a new strain. The FDA reclassification means that the burden of monitoring test 
performance for acceptability now appropriately resides with the manufacturer of the device, 
not solely with the laboratory. Improved performance of RIDTs may lead to a reduction in 
the amount of reflex testing to a molecular diagnostic test following a negative RIDT, which 
delays time to results and requires additional technical time and costs.
Timothy Uyeki: Before reclassification, for FDA clearance of any new RIDT, 
manufacturers only had to demonstrate equivalent performance to existing FDA-cleared 
tests. There were no standard levels of sensitivity and specificity to achieve. Now 
manufacturersmust demonstrate that RIDTs can meet improved sensitivity and specificity 
standards set by theFDA. Overall, this is a very positive development and long overdue. 
More accurate RIDTs, and importantly, RIDTs with higher sensitivity, will be very good for 
clinical management of influenza patients, primarily outpatients, because fewer false-
negative results will occur, especially during peak influenza activity. It will also be good for 
more accurate detection of influenza outbreaks, such as at long-term care facilities.
What are the strengths, limitations, and logistical challenges of molecular 
assays for influenza? What preanalytical or postanalytical factors should 
laboratories consider for rapid molecular testing performed at the POC?
Neil Anderson: The newly described CLIA-waived rapid molecular tests rival their antigen 
counterparts in terms of speed and simplicity. The primary benefit of rapid molecular tests is 
superior sensitivity over RIDTs, which may have a significant positive effect on overall 
influenza management. However, adoption of rapid influenza molecular testing requires 
justification for the added cost. This may be challenging, as hospitals currently using RIDTs 
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may perceive that they are already using a viable rapid test while underestimating the 
limitations of antigen testing. Emphasis should be placed on the benefits of added sensitivity, 
such as facilitating earlier treatment, improving outcomes, and preventing unnecessary 
hospital stays. These hidden costs may be difficult to capture but should be taken into 
account. Other challenges for clinical laboratories implementing POC molecular testing 
include procedures for proper instrument maintenance, including stringent cleaning 
protocols and periodic environmental testing, adherence to sterile technique, and training in 
all aspects of testing from preanalytical factors to postanalytical reporting of results.
Christine Ginocchio: As of June 2018, there are 7 CLIA-waived rapid molecular tests that 
include detection of influenza, either alone or in combination with respiratory syncytial virus 
(RSV), and one multiplex syndromic panel for a variety of respiratory pathogens. Rapid 
molecular tests are performed in enclosed cartridges or pouches, with a simple sample-to-
answer approach, requiring a few minutes of hands-on time with results in approximately 15 
min to 1 h. The strength of this testing is that it affords all healthcare organizations, 
including laboratories, physician practices, clinics, urgent care centers, and EDs, the ability 
to perform a simple yet very sensitive and specific test. Rapid molecular tests allow for 
round-the-clock near-patient testing, where clinical and infection control decisions can be 
rapidly made, rather than classically in a central laboratory, where result delays may occur. 
The major drawbacks of rapid molecular tests are increased cost over RIDTs and the need 
for instrumentation. However, the clinical benefits of an accurate rapid result may outweigh 
the increased cost.
Despite the simplicity of CLIA-waived rapid molecular tests, compliance with the test 
manufacturer’s instructions regarding all preanalytical and postanalytical phases of testing is 
still essential. Users must be trained, observed, and have knowledge of the information in the 
package insert, including all disclaimers and warnings. Quality control should be performed 
as recommended by the manufacturer. Appropriate collection of approved sample types must 
be followed to ensure assay performance. Since rapid molecular tests are performed in 
enclosed cartridges or pouches, amplicon contamination is virtually eliminated, but there is 
still a risk of environmental or user contamination. For example, administration of intranasal 
influenza vaccine in a room where samples are collected and tested could lead to false-
positive results. Healthcare workers with respiratory symptoms should refrain from testing 
or wear masks and clean gloves when collecting and testing samples to prevent self-
contamination of patient samples and testing areas. Testing areas and equipment surfaces 
should be appropriately cleaned, as recommended by the manufacturer. Users should also be 
familiar with reviewing test results to identify unusual patient results that should prompt 
repeat testing or an investigation. An unusually high number of invalid results may indicate 
user failure requiring supervision and retraining or reagent failure that should trigger an 
inquiry with the test manufacturer. Users must also be aware of and comply with local 
influenza reporting requirements.
Timothy Uyeki: Major strengths of rapid influenza molecular assays include high 
sensitivity, fast results (approximately 15–30 min), and the ability of some assays to also 
detect RSV nucleic acids. This last feature is especially helpful for testing young children 
with respiratory illness during the winter respiratory virus season. The limitations of rapid 
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molecular assays are similar to those for the RIDTs and include the inability to determine 
whether infectious virus is present, to differentiate influenza A virus subtypes, and to 
distinguish seasonal influenza A viruses from novel influenza A viruses. Despite improved 
sensitivity, end users of rapid molecular assays must keep in mind that a negative result does 
not altogether exclude influenza virus infection, although a negative result from a rapid 
molecular assay has much higher negative predictive value than for RIDTs.
Should influenza testing be performed in the setting of a centralized 
laboratory or available at the POC? Are there certain situations in which a 
dedicated influenza molecular test would be preferred over a multiplex 
assay that detects multiple agents of upper respiratory infection?
Ritu Banerjee: The clinical setting determines the preferred type of influenza testing. POC 
influenza testing is particularly useful in EDs and outpatient clinics,where timely results 
affect patient flow and clinical decisions. Influenza testing in a centralized laboratory is not 
ideal for these outpatient settings, as this requires specimen transport and increases 
turnaround time. However, centralized laboratories should still perform molecular tests for 
influenza, as more sensitive molecular tests are often needed when rapid antigen tests are 
negative, particularly with hospitalized, critically ill, and/or immunocompromisedpatients. 
During influenza season, when virus is circulating in the community and pretest probability 
of influenza virus infection is high, in most patients presenting with respiratory illness, use 
of a dedicated molecular test for influenza may be more useful and cost-effective than use of 
a multiplex assay containing several targets. However, during months when other respiratory 
viruses are circulating, or in immunocompromised patients who often harbor multiple 
pathogens, multiplex tests capable of detecting several targets may be useful.
Neil Anderson: There are many ways to implement molecular influenza testing. Although 
POC testing carries its own unique challenges, many hospitals may be willing to address 
these challenges in return for the benefit of faster results. The improvement in turnaround 
time can be particularly dramatic if a hospital normally relies on testing sent to anoffsite, 
centralized laboratory. If the difference in turnaround time between POC testing and a 
centralized laboratory is clinically negligible, it is preferable to test in a controlled 
environment by staff familiar with diagnostic testing, features that more commonly apply to 
centralized laboratories.
Another decision that must be made regarding implementation of influenza moleculartesting 
is the breadth of the testing offered. Current testing options range from tests that detect 
influenza viruses only to broadly multiplexed tests detecting 20 (or more) respiratory 
pathogens. Broad panels are typically more expensive and have lower analytical sensitivity 
thandedicated reverse transcription PCR tests. Broadly multiplexed tests continue to play an 
important role in the diagnosis of illness in patients at risk for severe respiratory disease 
from multiple pathogens, particularly immunocompromised patients.
Christine Ginocchio: Influenza testing is appropriate in both settings, depending on the 
patient population tested and the time to results. Ideally influenza testing should be 
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performed at the POC so that treatment decisions can be made in an appropriate timeframe 
to affect patient care. However, testing in a centralized laboratory can be as effective, 
particularly in the outpatient setting. High-throughput, random-access platforms are 
available that reduce technical time and provide results within hours.
Dedicated influenza testing is usually sufficient in the outpatient or ED setting or in an 
immunocompetent patient with no comorbidities when documented influenza is in the 
community. However, even in these settings, if the response to a negative influenza test is to 
automatically prescribe an antibiotic, a more comprehensive panel that identifies additional 
respiratory viruses should prevent antibiotic administration in a person with no risk factors 
for a concomitant bacterial infection. Additionally, in a patient with an unusual clinical 
presentation (such as pertussis in an adult), limiting the testing to influenza alone may miss a 
treatable disease. In the inpatient setting, the use of multiplex syndromic assays has been 
shown to decrease hospital length of stay, days of antibiotic and antiviral therapy, and 
number of ancillary tests and affect decisions to hospitalize or not. Multiplex syndromic 
assays have shown that coinfections with 1 or multiple respiratory viruses are not rare (up to 
30%–35% in children and 10%–15% in adults), indicating the need to identify all pathogens 
if cohorting of patients is necessary, especially during peak respiratory virus season. Finally, 
significant costs savings have been demonstrated with appropriate discontinuation of 
infection control measures when a respiratory pathogen aside from influenza was identified 
that did not require isolation. Notably, highly multiplexed syndromic testing is usually 
available through a centralized laboratory, rather than at the POC.
Timothy Uyeki: For outpatients with a clinical diagnosis of influenza, empiric antiviral 
treatment can be prescribed without influenza testing, especially for persons who are at high 
risk for complications from influenza or those with progressive disease. In the ambulatory 
care clinic setting, influenza testing using RIDTs or CLIA-waived rapid molecular assays is 
beneficial if having a rapid result will change clinical management. POC test results are 
usually available sooner than testing performed in a centralized laboratory becauseof the 
time required for specimen transport and processing, analysis, and result reporting. For most 
patients evaluated in an outpatient or ED setting who do not require hospital admission, a 
multiplex assay that detects multiple respiratory pathogens is not necessary, as there areno 
specific treatments available for respiratory viruses except for influenza virus infection.In 
hospitalized patients, particularly young children and the elderly, knowing whether a patient 
has influenza virus or RSV infection can be useful for diagnostic and infection prevention 
and control measures.
Kimberly Hanson: Rapid influenza testing should be available at the POC to enable clinical 
decision-making in real time. However, central laboratory testing is also useful for 
confirming a negative RIDT, subtyping, and for validating and testing lower respiratory tract 
specimen types such as bronchial alveolar lavage fluid. Additionally, current 
recommendations are that all hospitalized patients with influenza-like illness should have 
molecular testing performed. For most immunocompetent patients, influenza testing (with or 
without RSV) alone is likely adequate. For immunocompromised hosts and potentially 
critically ill patients (especially if rapid influenza testing is negative) a larger multiplex is 
preferred given the breadth of respiratory viruses than can cause severe disease.
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During influenza season, what is the effect of rapid molecular assays for 
influenza on the public health response?
Neil Anderson: Rapid molecular assays play a pivotal role in the public health response to 
influenza. The beginning of “influenza season” is often heralded by an increase in influenza-
testing positivity. This trigger is essential because it allows for the implementation of 
infection prevention, testing, and treatment protocols. The best illustration of the importance 
of this process is when it breaks down, as it did during the 2009 H1N1 influenza pandemic. 
During this time, most rapid influenza testing was performed using antigen-based assays that 
demonstrated extremely poor sensitivity for the circulating virus. These limitations resulted 
in delayed implementation of infection prevention measures and missed opportunities for 
patient treatment. Fortunately, much has changed in the past decade. A shift of rapid testing 
to more sensitive molecular methods decreases the likelihood of being caught off guard with 
the beginning of influenza season. Additionally, several manufacturers ofrapid molecular 
tests offer methods for centralized monitoring of results across multiple sites. This allows 
hospital systems to set up their own network for influenza virus detection, a useful tool that 
further aids public health efforts by both predicting the beginning of influenza season and 
monitoring for activity throughout.
Timothy Uyeki: The high sensitivity and rapidity of results produced by influenza 
molecular assays increases the potential for more accurate and expedient recognition of an 
influenza outbreak, particularly in an institutionalized setting such as a hospital or long-term 
care facility. Positive influenza testing results should prompt rapid implementation of 
infection prevention and control measures to decrease spread of influenza viruses in 
healthcare settings. Wider useof rapid molecular assays will detect more influenza virus 
infections and provide more accurate information than RIDTs for patients with influenza 
seeking medical care. Such data, if made available in a timely manner across the country, 
can be combined with traditional influenza surveillance data to provide public health 
officials with better situational awareness of high influenza activity in order to better direct 
response efforts. For example, medical counter-measures such as influenza vaccines and 
antivirals can be targeted to influenza “hotspots.” More accurate diagnosis of influenza can 
also contribute toward antimicrobial stewardship by reducing inappropriate empiric 
antibiotic prescriptions in patients who have influenzawithout severe illness. This can benefit 
public health by reducing unnecessary antibiotic use.Lastly, available molecular assays that 
distinguish among influenza A virus subtypes may facilitate recognition of suspected novel 
influenza A virus infections [i.e., influenza A positive,nonsubtypeable (H1, H3 negative 
results)]. Clinicians and laboratory staff who suspect detection of a novel influenza A virus 
infection should contact local or state public health officials as soon as possible to arrange 
specific testing by reverse transcription PCR; sequencing andfurther confirmation may be 
needed at the CDC.
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What does the future hold for influenza diagnostic testing? What types of 
tests will be available and in what settings will they be performed (central 
laboratories, clinics, pharmacies, homes, etc.)?
Ritu Banerjee: The future will likely see the development of even more sensitive, timely, 
and simple-to-use molecular POC tests for influenza detection. We will also likely see 
testing using self-collected specimens. Testing may even be performed at home, with 
accompanying provider consultation using telemedicine, or at community clinics or 
pharmacies, rather than in traditional hospital or clinic settings.
Christine Ginocchio: As both molecular testing prices and test turnaround times decrease, I 
anticipate that molecular assays will slowly but eventually replace most RIDTs because of 
better performance and overall cost savings when clinical impact is considered in the 
analyses. I also see an increase in more multiplex syndromic panels, for both hospitalized 
patients and in the outpatient setting, where there is the greatest opportunity to reduce the 
unnecessary use of antibiotics for persons with uncomplicated viral infections. A 
comprehensive diagnostic in combination with a POC assay for biomarkers of viral and/or 
bacterial disease will be essential to meet this goal. Additionally, as newer treatments 
become available for noninfluenza viral infections, comprehensive diagnostics will be 
necessary to target therapy. Influenza testing of the future should be available as CLIA-
waived or moderate complexity molecular tests that can be performed in a large variety of 
settings, ranging from the central laboratory (high throughput, fully automated, random 
access) to simple-to-use individual POC tests done in rapid response laboratories, EDs, 
clinics, and urgent care centers. Pharmacies should be able to test for influenza and 
immediately prescribe an antiviral. CLIA-waived diagnostics should be easily implemented 
in areas of “high-risk” exposure and transmission such as military bases and ships, college 
health centers, school nurses’ offices, company health units, and cruise ships. Rapid 
determination of the start of an influenza outbreak can help to reduce spread in the 
community. In-home testing by visiting nurses could ensure rapid recognition and treatment 
of an elderly, immunocompromised, or chronically ill patient at risk for rapidly progressing 
disease.
Kimberly Hanson: I envision home testing as a viable option in the future. Additionally, 
POC diagnostics will continue to improve in terms of sensitivity and simplicity and may 
potentially include subtype information, which can inform treatment choice.
Timothy Uyeki: As molecular technologies continue to advance, we will likely see further 
decreases in turn-around time and increased sensitivity. Influenza tests in the future will 
likely provide more actionable information, especially if based upon next-generation 
sequencing technology, and be able to distinguish among influenza A virus subtypes. The 
availability of tests that can detect infection with influenza viruses that are resistant to 
available antivirals will be important for clinical management. Some influenza molecular 
tests might be very portable (“laboratory in a box”) or even handheld devices for use in field 
investigations. Influenza tests could be available for over-the-counter use in the future, 
although a key issue will be the proper interpretation and use of the results. Having an over-
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the-counter influenza test might facilitate early antiviral treatment for some patients, as 
antiviral medications for influenza currently must be prescribed by a physician. Importantly, 
wider availability of testing does not replace clinical examination and assessment. Use of 
highly accurate influenza tests at pharmacies for patients with mild illness who are not at 
high risk for influenza complications, combined with antiviral treatment without the need for 
a prescription, could be considered under specific circumstances with sufficient supplies of 
antivirals. This strategy could alleviate the surge in patients at emergency rooms during 
seasonal epidemics and rare pandemics.
Neil Anderson: Although molecular influenza assays are likely to become faster and even 
more user-friendly, the real “breakthroughs” will be how these tools are used to better 
patient care and public health. Future directions for improvement likely lie in greater patient 
access to testing and results. Rapid antigen tests for a variety of infectious diseases found 
their greatest utility when they were used to bring testing to patients outside of the hospital. 
As molecular assays become more user-friendly and cost-effective, they may be offered 
through mobile clinics, pharmacies, schools, grocery stores, and gyms. In the future, small 
rapid molecular platforms may even reside in personal residences.
Examples of increased patient access to results already exist, as many healthcare systems 
now provide real-time access to portions of the medical record, including test results. Some 
laboratories have even more proactive approaches such as sending patients text messages 
when their results are ready. As many rapid molecular tests feed results into a centralized 
data repository, these tests are already poised for electronic reporting. The prospect of cloud-
based data aggregation for influenza is particularly exciting. Imagine an app that reports 
your influenza test result in addition to real-time positivity rates in your local area. In this 
digital age, it is natural and desirable that reporting mechanisms and clinical laboratories 
should evolve with the capabilities of technology.
Nonstandard abbreviations:
7
POC point-of-care
FDA US Food and Drug Administration
ED emergency department
RIDT rapid influenza diagnostic (antigen) tests
RSV respiratory syncytial virus
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